Braf-Mutant Colorectal Cancer
Research spotlight: Novel regimens demonstrate efficacy in colorectal cancer
March is Colorectal Cancer Awareness Month.
Four actionable targets for metastatic colorectal cancer that APPs should know
Treatment options for patients with metastatic colorectal cancer are limited and, therefore, many clinicians and researchers are focused on identifying predictive and prognostic molecular targets for this disease.
FDA approves Braftovi with Erbitux for metastatic colorectal cancer subset
The FDA approved encorafenib in combination with cetuximab for adults with previously treated BRAF V600E-mutant metastatic colorectal cancer.
Encorafenib regimens confer quality-of-life, survival benefit in BRAF V600E-mutant metastatic colorectal cancer
A combination of encorafenib and cetuximab, with or without binimetinib, demonstrated significant improvement in patient-reported quality-of-life assessments compared with standard-of-care chemotherapy among patients with BRAF V600E-mutant metastatic colorectal cancer, according to results of the randomized phase 3 BEACON CRC study scheduled for presentation at Gastrointestinal Cancers Symposium.
Triplet therapy improves outcomes in BRAF V600E-mutant metastatic colorectal cancer
BARCELONA, Spain — Triplet therapy with encorafenib, cetuximab and binimetinib significantly extended OS compared with standard treatment for patients with BRAF V600E mutation-positive metastatic colorectal cancer, according to results of the phase 3 BEACON CRC trial presented at European Society for Medical Oncology Congress.